News and Announcements
Kazia, a company developing innovative high-impact drugs for cancer, presents to AusBiotech Invest
- Published November 04, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia, developing innovative, high-impact drugs for cancer has presented to AusBiotech Invest.
Investment Rationale:
- Our lead program, GDC-0084, was designed by Genentech, the world’s most successful cancer drug developer, and has completed a successful phase 1 human trial, showing it to be generally safe and providing signals of efficacy
- GDC-0084 is a PI3K inhibitor, a well-validated and well-understood class of cancer therapies with four FDA-approved products; unique differentiating feature of GDC-0084 is the ability to cross the blood-brain barrier
- Five clinical trials of GDC-0084 are currently underway at leading US hospitals, of which four are primarily funded by external parties, covering a broad range of primary and secondary brain cancers to provide multiple shots on goal
- Company is well-financed, following a recent institutional placement, with new interim efficacy data from lead program expected in November 2019; pivotal study for registration expected to commence in 2020
Read Full Article
For more information on Kazia register your interest below.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
